- Identification and assessment of first-in-class molecular targets , with a particular focus on earlystage programs for which clinical utility has yet to be
evaluated , as well as literature reviews on novel molecular targets .
- Assessment of the licensing and co-development deal landscape for pain therapeutics , and benchmarking of deals involving first-in-class versus non-first-in-class-products .
Reasons to buy
- Understand the current clinical and commercial landscape , including a comprehensive study of disease pathogenesis , diagnosis , prognosis and the available treatment options available at each stage of diagnosis .
- Visualize the composition of the pain markets in terms of dominant molecule types and targets , highlighting what the current unmet needs are and how they can be addressed . This knowledge allows a competitive understanding of the gaps in the current market .
Download sample Copy of This Report at : http :// www . radiantinsights . com / research / frontier-pharma-chronic-acute-andneuropathic-pain-gpcr-and-nerve-growth / request-sample
- Analyze the pain pipeline , stratified by pain subtype , stage of development , molecule type and molecular target .
- Assess the therapeutic potential of first-in-class targets . Using a proprietary matrix , first-in-class products have been assessed and ranked according to clinical potential . Promising early-stage targets have been further reviewed in greater detail .
- Identify commercial opportunities in the pain deals landscape by analyzing trends in licensing and co-development deals , and producing a list of pain therapeutics that are not yet involved in deals and may be potential investment opportunities .
Table of Contents 1 Table of Contents 2 1.1 List of Tables 2 1.2 List of Figures 3
2 Executive Summary 4
Follow Us :